Early Study Finds Eprenetapopt Plus Azacitidine Promising in TP53-Mutant MDS/AML

(MedPage Today) -- Study Authors: David A. Sallman, Amy E. DeZern, et al.Target Audience and Goal Statement: Oncologists, hematologistsThe goal of this study was to examine the efficacy and safety of the first-in-class small molecule eprenetapopt...